Level D· Scientific groundwork from lab and animal studiesAnimal StudyEurope PMCOpen access

A catechol-modified quaternized chitosan/PEG hydrogel for diabetic wound healing: synergistic effects of TGF-β3 delivery, angiogenesis, and antibacterial activity

Yang X., Zhang ZC., Liu B., Lu YN., He XY., Chen HD.

Animal Study on Diabetic Foot, Chronic Wound, published in Front Cell Infect Microbiol (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Front Cell Infect Microbiol (2025)
Reported sample size
—
Source database
Europe PMC
PMID
41425964
PMCID
PMC12714989
DOI
10.3389/fcimb.2025.1717082

Abstract (original English)

Background Diabetic foot ulcers (DFUs) represent a challenging chronic wound model, often plagued by biofilm formation that sustains inflammation and impedes healing. Transforming growth factor-beta 3 (TGF-β3) is a promising cytokine for tissue regeneration, yet its delivery within the hostile, infected wound milieu remains problematic. This study addresses the intertwined challenges of microbial resistance and healing impairment by developing a multifunctional injectable hydrogel that couples inherent antibacterial activity with sustained TGF-β3 release. Methods A catechol-modified quaternized chitosan (QCS-Catechol) was synthesized and crosslinked with benzaldehyde-terminated 4-arm polyethylene glycol (4-arm PEG-CHO) to form the BP-QS/TGF-β3 hydrogel. Its physicochemical properties, injectability, adhesion, and mechanical strength were characterized. Antibacterial efficacy was evaluated against Staphylococcus aureus and Escherichia coli . The biocompatibility and therapeutic potential of the BP-QS/TGF-β3 hydrogel were evaluated through in vitro assays (CCK-8, apoptosis, hemolysis) and in a streptozotocin-induced diabetic mouse model, respectively, against controls including PBS, BP-QS (blank hydrogel), and free TGF-β3 solution. Wound closure kinetics, histology (H&E, Masson's trichrome), and immunohistochemistry (CD31, Ki-67) were analyzed. Results The BP-QS/TGF-β3 hydrogel d

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
AnimalsHumansMiceEscherichia coliStaphylococcus aureusDiabetic FootDiabetes Mellitus, ExperimentalDisease Models, AnimalPolyethylene GlycolsCatechols

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research